MonotherapyMonotherapyCombination with ipilimumab & nivolumab (CTLA-4 & PD-1 inhibitors)Rationale: CBL0137 has been shown to inhibit cancer stem cell growth and tumor growth, demonstrating promising results when combined with existing therapies that attack tumor cells (chemo/immunotherapy) (68). Here, PDCD1 is linked to cancer.